SciSparc Announces Recruitment of First Patient for its Phase IIa Clinical Trial in Alzheimer’s Disease
Ryan Allway January 6th, 2022 The clinical trial will be conducted at The Israeli Alzheimer’s Medical Center and will evaluate the safety, tolerability and efficacy of SCI-110 in patients with Alzheimer’s disease and agitation TEL AVIV, Israel, Jan. 6, 2022 /PRNewswire/ — SciSparc Ltd. (NASDAQ: SPRC) (the “Company”), a clinical-stage pharmaceutical... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )